Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure

• Published in: Oncology letters 2024-11, Vol.28 (5), p.1, Article 504
• Main Authors: Li, Meifang, Lin, Cheng, Lin, Jinghui, Chen, Shijie, Weng, Lihong, He, Zhiyong
• Format: Article
• Language: English
• Subjects: Analysis; Apoptosis; Biopsy; Cancer; Cancer therapies; Care and treatment; Cell death; Chemotherapy; Development and progression; Epidermal growth factor; Immunohistochemistry; Immunotherapy; Kinases; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Medical research; Medicine, Experimental; Methods; Mutation; Patient outcomes; Patients
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2024.14637

Treatment options for epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) following tyrosine kinase inhibitor (TKI) failure are limited, and platinum-based chemotherapy remains the main treatment. The development of effective immunotherapy for this disease has been challenging. In the present study, 37 patients with EGFR-mutant advanced NSCLC who were treated with programmed cell death-1 (PD-1) inhibitor-based combinations after TKI failure were reviewed. The total cohort had a median progression-free survival (mPFS) of 5.2 months (95% CI, 4.077-6.323 months) and a median overall survival (mOS) of 18.3 months (95% CI, 12.932-23.668 months). Patients with Eastern Cooperative Oncology Group performance-status (ECOG-PS) scores of 0 or 1 had longer mPFS than those with ECOG-PS scores of 2 (5.4 vs. 2.4 months; P=0.006). In addition, a PFS benefit was observed in patients with EGFR T790M-negative compared with EGFR T790M-positive tumors (mPFS 6.2 vs. 4.4 months; P=0.041). Patients treated with immunotherapy-based combinations as a front-line therapy had a longer mPFS than those in which the combinations were used as a late-line therapy (6.2 vs. 2.4 months; P